Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …

Background Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit
from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones …

Liquid biopsies offer the potential to monitor cancer response and resistance to therapeutics
in near real-time. However, the plasma cell free DNA (cfDNA) level can be low and the …

Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of
Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and …

Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to
imatinib, with the notable exception of the most common mutation, D842V. Avapritinib is a …

Gastrointestinal stromal tumors (GISTs) are common neoplasms of the gastrointestinal tract
that can be treated successfully using C-kit target therapy and surgery; however, imatinib …

The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either
the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors
originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for …